Navigation Links
Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
Date:5/11/2010

LIUZHOU CITY, China, May 11 /PRNewswire-Asia-FirstCall/ -- China Baicaotang Medicine Ltd. (OTC Bulletin Board: CNBI) ("CBT," or the "Company"), a provincial leader in pharmaceutical distribution and retailing in the Guangxi Province of China announced today that Harbinger Research, LLC, an independent equity research firm, will provide research coverage on the Company.

Mr. Tang Hui Tian, Chairman and CEO of CBT, stated that "Our Company is in the midst of growth and expansion in Guangxi province, and given our status as a U.S.-traded Company and plans to up-list to a national exchange in the near future, we feel Harbinger Research's coverage of CBT comes at an excellent time for CBT and its investors. We believe our company and industry will continue to demonstrate robust growth for years to come, as per-capita disposable income and government-driven pharmaceutical spending in China continue to grow."

Brian R. Connell, CFA, a Harbinger Research Senior Analyst, stated that, "We are excited to initiate coverage on China Baicaotang, which we believe is significantly undervalued on both a relative and absolute basis. We expect the pharmaceutical industry to remain strong in China for the foreseeable future, clearly benefiting all provincial industry leaders, including China Baicaotang."

To view Harbinger Research's coverage initiation on China Baicaotang Medicine, Ltd., rated by Brian R. Connell, CFA, please click on the following link: http://www.harbingerresearch.com/link/13/253/CNBI

About China Baicaotang Medicine, Ltd.

China Baicaotang is a vertically-integrated pharmaceutical company that operates in the Guangxi Province of China. The Company's three operating subsidiaries include a drug and herbal remedy manufacturing company, a pharmaceutical distributor that carries over 8,000 products, and a retail drugstore chain with 66 stores throughout the Guangxi province. The company is an emerging leader in this region of the PRC, and its shares currently traded on the OTC:BB under the symbol CNBI. Learn more http://www.china-bct.com .

About Harbinger Research, LLC

Harbinger Research is an independent equity research that employs a research team consisting entirely of CFA charter holders and follows a number of companies across a wide variety of industries. Harbinger Research makes all of its reports available through its website at http://www.harbingerresearch.com , and also distributes content through a variety of partners, including InvestorsInsight Publishing, and through most major financial portals.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

    For more information, please contact:

    China Baicaotang Medicine, Ltd. Investor Contact:
     Shelly Zhang
     Chief Financial Officer
     China Baicaotang Medicine Limited
     Email: z_shelly@hotmail.com
     Tel:   +86-772-363-8318
     Web:   http://www.china-bct.com


'/>"/>
SOURCE China Baicaotang Medicine Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
2. Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. UCLA researchers use new microscope to see atoms for first time
5. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
6. Knome Announces KnomeDISCOVERY Research Awards Program
7. The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research
8. Web-Based Management Suite Supports Complex Research Consortia
9. German MedSys Project Adopts Genedata Phylosopher for Research Informatics
10. New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher
11. Materials research advances reliability of faster smart sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):